C-Terminal Fragment of Adiponectin Receptor Clinical Correlations

The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre-diabetic assessment (n = 240). Patients with inflammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies (n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10) were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and inflammation. Patients using anti- TNF α therapies (Remicade® Infliximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without significant weight changes and the within patient variability was <10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specificity. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive value criteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.